Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0699790 (colon cancer)
 28,837 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We report three cases of complete response (CR) after treatment with UFT/LV for recurrent colorectal cancer. Case 1: A 44-year-old man was diagnosed with multiple liver metastases after resection of cecal cancer. UFT (500 mg/day)/Leucovorin (75 mg/day) was administered. Metastatic lesions of the liver completely disappeared on computed tomography(CT)one month after chemotherapy. Grade 2 hyperbilirubinemia and grade 1 diarrhea, pigmentation and rash were recognized. No signs of recurrence were observed for 35 months. Case 2: A 66-year-old man who underwent left colectomy and partial hepatectomy for transverse colon cancer and descending colon cancer with liver metastasis was determined to have multiple lung metastases. UFT/LV therapy was started. The lung lesions became only scars 7 months later. Adverse events were not seen. No other recurrence was found over 20 months. Case 3: A 66- year-old woman was detected with a lymph node recurrence after surgery for rectal cancer. CT revealed the disappearance of the tumor after 7 courses of UFT/LV therapy. Grade 2 hyperbilirubinemia appeared. Recurrence was not observed for 22 months, and the treatment has been discontinued.
 ...
PMID:[Three cases of complete response after treatment with UFT and leucovorin for recurrent colorectal cancer]. 1901 50

Oral tegafur/uracil (UFT)/Leucovorin (LV) therapy has been used for chemotherapy for advanced colorectal cancer with anti-cancer effects the same as conventional 5-fluorouracil and Leucovorin (5-FU/LV). However, the effectiveness and safety of UFT/LV in the treatment of elderly patients with advanced colorectal cancer is not evaluated. We report a case of multiple lymph node metastases from colon cancer successfully treated with UFT/LV. An 81-year-old man had been admitted to our hospital because of left neck and axillary mass, which was diagnosed as transverse colon cancer with multiple lymph node metastases. After a laparoscopic partial resection of transverse colon, UFT/LV (UFT 300 mg/m2/day and LV 75 mg/day) was administered for 4-week-on and 1-week-off. After the administration of the chemotherapy, a good partial response of these metastatic lymph nodes was achieved. No grade 3 or more severe adverse reactions have been observed. He has now survived for 14 months without a recurrence after the administration of the chemotherapy. This case suggests the effectiveness and safety of UFT/LV in elderly patients with colorectal cancer.
 ...
PMID:[A case of multiple lymph node metastases from transverse colon cancer successfully treated with oral tegafur/uracil (UFT)/Leucovorin (LV)]. 1910 58

Many patients with stage III colon cancer, and selected patients with stage II disease, will obtain significant benefit from adjuvant chemotherapy. Combination regimens that include a fluoropyrimidine plus oxaliplatin are the current standard of care, based on findings from the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) and the National Surgical Adjuvant Breast and Bowel Project (NSABP) C-07 trials. Ongoing randomized trials are evaluating oral fluoropyrimidines combined with oxaliplatin and the addition of targeted therapies to oxaliplatin-based regimens for use in colon cancer adjuvant treatment. Adjuvant treatment approaches for patients with rectal cancer (stage II and III) now include preoperative chemoradiotherapy, based on a phase III comparison of preoperative vs. postoperative chemoradiotherapy conducted in Germany. Ongoing trials are evaluating new cytotoxic and target-oriented agents used in both the neoadjuvant and adjuvant settings in these patients. Improved surgical and radiotherapy techniques may also contribute to superior patient outcomes. Additional research is needed to identify patient subgroups at risk for recurrence, predictive factors for treatment response, and better treatment strategies for patients with colon and rectal cancer.
 ...
PMID:Adjuvant treatment of colorectal cancer. 1934 49

The patient was a 41-year-old female, who underwent histectomy and sdnexopexy due to perforated ovarian tumor. One month later, she was diagnosed with simultaneous bilateral metastatic ovarian tumor of colon cancer, and right hemicolectomy (D3) was performed. After surgery, the patient was treated with 10 courses of therapy with the FOLFOX4 regimen. No recurrence was recognized, and the patient was treated with 12 courses of therapy with oral tegafur/ uracil (UFT)+oral Leucovorin (LV). The patient evidenced no tumor recurrence 2 years after the initial treatment. We consider oral UFT+oral LV therapy was useful for post FOLFOX4 therapy after R0 surgery.
 ...
PMID:[A case of simultaneous bilateral metastatic ovarian tumor of colon cancer followed by FOLFOX4 Regimen and oral tegafur/uracil+oral leucovorin after R0 operation]. 1975 39

A69-year-old man was diagnosed with sigmoid colon cancer and underwent resection of the sigmoid colon. He was later diagnosed with multiple liver metastases 11 months after resection of the sigmoid colon cancer. He was treated by intraarterial chemoembolization using degradable starch microspheres (DSM) and radiofrequency ablation therapy. As a systemic therapy, combined oral administration of tegafur/uracil (UFT) and Leucovorin(Uzel) was started (UFT 450 mg/day, Leucovorin 75 mg/day, 4 weeks of therapy followed by a 1-week treatment break). Two months after 4 courses, the liver metastases had markedly diminished and CEA was within the normal range. The metastases had almost disappeared and tumor markers decreased to within normal limits. This treatment was very safe and effective. Such a strategic multidisciplinary treatment can lead to a better prognosis for colorectal cancer with liver metastases.
 ...
PMID:[Multiple liver metastases due to sigmoid colon cancer successfully treated by degradable starch microspheres (DSM)-TAE, radiofrequency ablation therapy, and Uzel/UFT]. 2015 97

The patient was a 75-year-old man who was admitted because of diarrhea and anemia. Endoscopic examination revealed advanced sigmoid colon cancer. Serum CEA levels were markedly elevated. In July 2007, surgery was performed, but the sigmoid colon cancer was unresectable. After surgery, the patient was treated with chemotherapy and concurrent radiotherapy. The chemotherapy consisted of oral UFT (420 mg/body/day)and Leucovorin (75 mg/body/day) administered for 6 weeks. Radiotherapy at 2 Gy/day was administered 30 times (total dose 60 Gy). The tumor decreased slightly in size and serum CEA levels also decreased. The patient refused surgery as an additional therapy. In August 2007, we started combination chemotherapy using oral S-1 (100 mg/body/day, day 1-14) and intravenous CPT-11 (140 mg/body/day, day 1 and 15) as one course for 4 weeks. After 4 courses, serum CEA levels were normal, the sigmoid colon cancer was not found by endoscopy and a biopsy specimen revealed no malignant cells. Moreover, after 8 courses, the tumor disappeared, as confirmed by computed tomography (CT) and positron emission tomography-CT, representing a complete response. Chemoradiotherapy using UFT and Leucovorin, and chemotherapy consisting of S-1 and CPT-11 as an additional therapy may be effective for treating unresectable advanced sigmoid colon cancer.
 ...
PMID:[A case of effective chemotherapy using S-1 and CPT-11 following chemoradiotherapy with UFT and Leucovorin for unresectable advanced sigmoid colon cancer]. 2033 98

Leucovorin is a reduced form of folic acid, which has multiple uses.(1) In this case report, it is used in combination with fluorouracil in the treatment of colon cancer. We describe a 53-year-old male, who was started on FOLFOX 6 + bevacizumab who experienced a hypersensitivity reaction to leucovorin. There have been very few cases of leucovorin hypersensitivity reactions reported in the literature. In this case, symptoms include flushing, hives, body pain, headaches, elevated blood pressures, and general discomfort. Although leucovorin reactions are considered rare, one should be aware of the types of reactions that can occur with leucovorin.
 ...
PMID:Leucovorin-induced hypersensitivity reaction. 2124 70

The efficacy of oxaliplatin monotherapy against several solid tumors and its relative lack of nephrotoxicity and myelosupression, coupled with results of the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer trial, led to a great deal of interest for the implementation of this chemotherapeutic agent in the preoperative setting for the management of adenocarcinoma of the rectum. Despite limited in-vitro and in-vivo data with regard to the radiosensitizing properties of oxaliplatin in rectal cancer, it rapidly entered phase I-III clinical trials. This study reviews the results of these trials and the current status of oxaliplatin as a radiosensitizing agent in the neoadjuvant management of rectal cancer.
 ...
PMID:Oxaliplatin as a radiosensitizing agent in rectal cancer. 2128 66

A 73-year-old man was referred to our hospital with sigmoid colon cancer in July 2009. CT and MRI showed synchronous multiple liver metastasis. After a sigmoid colon resection in August, he received convergent chemotherapy in combination with 5-fluorouracil(5-FU)/Leucovorin(LV)(RPMI regimen)and bevacizumab for liver metastasis. After two courses without any major adverse effects, liver metastasis remarkably reduced on CT and MRI examination. We thus performed a liver resection, and pathological examination revealed a complete response in liver. Combination chemotherapy of 5-FU/LV and bevacizumab can be expected to provide safe and effective treatment for liver metastasis of colon cancer.
 ...
PMID:[A case of synchronous multiple liver metastasis of sigmoid colon cancer with a pathological complete response to combination chemotherapy of 5-FU/LV and bevacizumab]. 2136 5

The prognosis of patients with advanced colorectal cancer with icterus is dismally poor, and adequate chemotherapy for these patients has not been established yet. A 59-year-old male with fatigue, anorexia and icterus with serum total bilirubin 9.7 mg/dL was referred to our institution. He was diagnosed with advanced sigmoid colon cancer with multiple liver metastases. A biopsy specimen of the primary tumor showed well-differentiated adenocarcinoma without KRAS mutation. Since biliary drainage was impossible due to diffuse liver metastases, we initiated combination chemotherapy with 5-fluorouracil, Leucovorin, oxaliplatin (modified FOLFOX6) and cetuximab. The doses of 5-fluorouracil and oxaliplatin were reduced, but cetuximab was administered at the standard dosage. After 3 courses of chemotherapy, total bilirubin dropped to 0.8 mg/dL. No significant toxicity other than grade-2 skin toxicity and neuropathy was observed, and the patient has continued chemotherapy on an outpatient basis. Combination chemotherapy with mFOLFOX6 plus cetuximab was effective and feasible in this case of metastatic colon cancer with icterus due to diffuse liver metastasis.
 ...
PMID:FOLFOX plus cetuximab for a patient with metastatic colorectal cancer with icterus due to multiple liver metastases. 2177 13


<< Previous 1 2 3 4 5 6 7 8 Next >>